NCT06792214View on ClinicalTrials.gov

Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

January 3, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
SARS CoV-2 Post-Acute Sequelae
Interventions
DRUG

Nirmatrelvir/ritonavir

Paxlovid PO BID for 5 days + standard of care

DRUG

Remdesivir

Veklury IV daily for 5 days + standard of care

Trial Locations (4)

K7L 2V7

NOT_YET_RECRUITING

Kingston Health Sciences Centre, Kingston

L2S 0A9

NOT_YET_RECRUITING

Niagara Health System, St. Catharines

M5G 1X5

RECRUITING

Mount Sinai Hospital, Sinai Health System, Toronto

M6R 1B5

NOT_YET_RECRUITING

St. Joseph's Health Centre, Unity Health Toronto, Toronto

All Listed Sponsors
collaborator

Unity Health Toronto

OTHER

collaborator

Kingston Health Sciences Centre

OTHER

collaborator

Niagara Health System

OTHER

lead

Mount Sinai Hospital, Canada

OTHER

NCT06792214 - Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial | Biotech Hunter | Biotech Hunter